GeoVax Labs to Attend BIO International Convention May 3-6, 2010 in Chicago at McCormick Place; Exhibiting at Booth 1631 in Georgia Pavilion

ATLANTA, April 29 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVXD), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is participating in the BIO International Convention (BIO2010) taking place May 3-6, 2010 in Chicago, IL at McCormick Place. This event, hosted by the Biotechnology Industry Organization (BIO), will feature high-level industry leaders discussing public policy issues of critical importance to all segments of the biotechnology industry, including health and medicine, food and agriculture, industry and environment and emerging companies. Thousands of business leaders, scientists, executives, investors and industry leaders attend this annual BIO event.

GeoVax is exhibiting at the BIO Show within the Georgia Pavilion, Booth Number 1631. Exhibit hours are 10:00 am - 6:30 pm on May 4 and 9:00 am - 5:00 pm on May 5 and 6.

President and CEO Dr. Robert McNally, along with other Company executives, will attend the Partnering for Global Health Forum 2010, a conference within the convention designed to connect people and ideas to save lives in the developing world and focus on market-based solutions that will help speed the development of drugs, vaccines and diagnostics for the world's poorest people.

Dr. McNally and colleagues will be available to meet with interested conference attendees at Booth Number 1631 within the Georgia Pavilion and its meeting room, to discuss how the Company's therapeutic vaccine for those infected with HIV may improve treatment options.  In addition, Company executives anticipate meetings with the CMOs and manufacturers of the Company's HIV/AIDS vaccines; with its contacts at analytical laboratories with which it is currently working; and with some of the Company's research partners.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. For more information, please visit www.bio.org.

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus -- that leads to AIDS) and other infectious agents.  Our goals include developing HIV/AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines have demonstrated the ability to raise anti-HIV immune responses as well as for their safety.  Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will involve 225 participants at sites in the United States and South America.  Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax.  For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

SOURCE GeoVax Labs, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED